CS
INBX

Candriam SCA’s Inhibrx, Inc. Common Stock INBX Stock Holding History

Candriam SCA’s Portfolio INBX Stock Details INBX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		– Sell
-135,069
Closed -$5.13M – 750
2023
Q4 		$5.13M Sell
135,069
-20,000
-13% -$429K 0.04% 329
2023
Q3 		$2.85M Sell
155,069
-32,000
-17% -$670K 0.02% 393
2023
Q2 		$4.86M Hold
187,069
– – 0.04% 336
2023
Q1 		$3.25M Hold
187,069
– – 0.02% 464
2022
Q4 		$4.61M Sell
187,069
-100,000
-35% -$2.94M 0.03% 397
2022
Q3 		$5.15M Sell
287,069
-65,000
-18% -$1.17M 0.04% 371
2022
Q2 		$4M Buy
352,069
+84,632
+32% +$1.25M 0.03% 359
2022
Q1 		$5.96M Sell
267,437
-107,889
-29% -$2.75M 0.04% 319
2021
Q4 		$16.4M Buy
+375,326
New +$15M 0.1% 199

Other funds holding INBX

Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $3.5B AUM 1,165.83% 1-Year Est. Return
SI
Sofinnova Investments Menlo Park, California $2.63B AUM 117.41% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
AAM
Alpine Associates Management Palm Beach, Florida $1.7B AUM 97.55% 1-Year Est. Return

Candriam SCA's INBX Position: Q1 2024 in Review

Candriam SCA sold out of Inhibrx, Inc. Common Stock (INBX) in Q1 2024, closing a stake of 135,069 shares — an estimated $5.13M sold.

Candriam SCA first reported a position in INBX in Q4 2021 and held it in 9 quarters. The position peaked at $16.4M in Q4 2021. 126 funds tracked by Wall St. Rank hold INBX as of Q1 2024.

  • Candriam SCA reported no remaining Inhibrx, Inc. Common Stock position as of Q1 2024 after selling out during the quarter.
  • Candriam SCA sold 135,069 Inhibrx, Inc. Common Stock shares in Q1 2024, an estimated $5.13M.
  • Candriam SCA first reported a position in Inhibrx, Inc. Common Stock in Q4 2021 and held it in 9 quarters.
  • Candriam SCA's Inhibrx, Inc. Common Stock position peaked at $16.4M in Q4 2021.
  • 126 funds tracked by Wall St. Rank held Inhibrx, Inc. Common Stock as of Q1 2024.

Based on Candriam SCA's 13F filing for Q1 2024, filed 6 May 2024.